Mevion Medical Systems announced today that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning in a comprehensive hospital in Southern China.
Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. HYPERSCAN PBS improves on these benefits by using Mevion’s unique Adaptive Aperture® pMLC to enable faster and sharper delivery of therapeutic radiation to tumors while sparing healthy tissue.
The MEVION S250i Proton Therapy System’s leading-edge clinical capabilities, combined with its compact, affordable design, and industry-leading ramp-up time, have changed the landscape of proton therapy. Mevion received US FDA 510 clearance for the system in 2017 and is actively seeking regulatory approval from the National Medical Products Administration in China.
“We are proud to be selected to equip a new proton center in Southern China,” said Tina Yu, Ph.D., CEO, and President of Mevion Medical Systems. “It confirms Mevion’s leading position as a trusted compact proton therapy provider and marks another milestone of our growth in China.”
According to Global Cancer Observatory, there were over 4.5 million cancer cases in China in 2020. However, only 3 proton centers are currently in clinical operation in Mainland China, leaving a substantial number of patients without access to this advanced cancer-fighting technology. As the innovator of the single-room system, Mevion’s approach allows for an expedited project timeline, efficient center operation, and financial success, all of which will benefit the underserved China market.
